Biotech investing easy as ABC: Contractor agrees work for stock deal

By Gareth Macdonald

- Last updated on GMT

ABC to take stock in firm treating cancer with lasers and shells
ABC to take stock in firm treating cancer with lasers and shells

Related tags Immune system Oncology

ABC Laboratories has agreed to provide privately-owned cancer vaccine firm Immunophotonics with development services in exchange for company stock.

The Missouri-based contract research organisation (CRO) ABC has been helping develop Immunophotonics’ lead product inCVAX – a candidate vaccine for solid tumours - for several years in a services agreement.

The CRO’s decision to continue this work in exchange for stock reflects Immunophotonics’ confidence in ABC’s ability “to continue to provide the highest quality analytical support for our inCVAX project” ​according to the biotech's chief drug development officer, Joe Raker.

ABC CEO John Bucksath was similarly enthusiastic about the partnership; describing Immunophotonics’ approach to treating cancer as having “has great potential to help patients in need​.”

Cancer vaccine

Immunophotonics’ lead product is part of a two injection cancer treatment. The first shot is used to guide a fibre optic cable that targets a laser that heats the tumour, which prompts it to release antigens.

A second injection then delivers a glucosamine polymer - called N-dihydro-galacto-chitosan (GC)​ - that activates immune cells, exposing them to the tumour antigens thereby generating a tumour specific T-cell response.

The glucosamine polymer is also called Protectin, which is derived from a type of glucose called chitin found in crustacean shells.

inCVAX has already been examined in Phase II clinical trials in Peru and the Bahamas​.

Investment

ABC joins existing Immunophotonics backers Cultivation Capital, St. Louis Arch Angels, Billiken Angels and the Missouri Technology Corporation, which took part in a $2.48m (€2.2m) Series A financing round in January​.

At the time Immunophotonics said it would use the cash to fund trials in Latin America and the US.

ABC also holds stock in cancer drug firm Euclises Pharmaceuticals – which is developing COX-2 inhibitors - through an investment made last September last.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines